Artículo
Glucosylpolyphenols as Inhibitors of Aβ-Induced Fyn Kinase Activation and Tau Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer's Disease
Autor/es | De Matos, Ana M.
Blázquez Sánchez, M. Teresa Bento Oliveira, Andreia de Almeida, Rodrigo F.M. Nunes, Rafael Lopes, Pedro E.M. Machuqueiro, Miguel Cristóvão, Joana S. López López, Óscar Fernández-Bolaños Guzmán, José María Amélia P. |
Departamento | Universidad de Sevilla. Departamento de Química orgánica |
Fecha de publicación | 2020 |
Fecha de depósito | 2022-11-28 |
Publicado en |
|
Resumen | Despite the rapidly increasing number of patients suffering from type 2 diabetes, Alzheimer's disease, and diabetes-induced dementia, there are no disease-modifying therapies that are able to prevent or block disease ... Despite the rapidly increasing number of patients suffering from type 2 diabetes, Alzheimer's disease, and diabetes-induced dementia, there are no disease-modifying therapies that are able to prevent or block disease progress. In this work, we investigate the potential of nature-inspired glucosylpolyphenols against relevant targets, including islet amyloid polypeptide, glucosidases, and cholinesterases. Moreover, with the premise of Fyn kinase as a paradigm-shifting target in Alzheimer's drug discovery, we explore glucosylpolyphenols as blockers of Aβ-induced Fyn kinase activation while looking into downstream effects leading to Tau hyperphosphorylation. Several compounds inhibit Aβ-induced Fyn kinase activation and decrease pTau levels at 10 μM concentration, particularly the per-O-methylated glucosylacetophloroglucinol and the 4-glucosylcatechol dibenzoate, the latter inhibiting also butyrylcholinesterase and β-glucosidase. Both compounds are nontoxic with ideal pharmacokinetic properties for further development. This work ultimately highlights the multitarget nature, fine structural tuning capacity, and valuable therapeutic significance of glucosylpolyphenols in the context of these metabolic and neurodegenerative disorders. |
Agencias financiadoras | European Commission (EC) Fundação para a Ciência e a Tecnologia. Portugal Gobierno de España Junta de Andalucía |
Identificador del proyecto | GA 612347
SFRH/BD/93170/2013 SFRH/BD/116614/2016 PD/BD/142847/2018 SFRH/BD/145600/2019 CEECIND/03414/2018 CEECIND/02300/2017 UIDB/00100/2020 UIDB/04046/2020 UIDB/04378/2020 IF/00780/2015 CTQ2016-78703-P FQM134 |
Cita | De Matos, A.M., Blázquez Sánchez, M.T., Bento Oliveira, A., de Almeida, R.F.M., Nunes, R., Lopes, P.E.M.,...,Amélia P., (2020). Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer's Disease. Journal of Medicinal Chemistry, 63 (20), 11663-11690. https://doi.org/https://dx.doi.org/10.1021/acs.jmedchem.0c00841. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Glucosylpolyphenols as Inhibit ... | 1.859Mb | [PDF] | Ver/ | |